| 034L466 |
| 82034-46-6 |
| AB00698349_08 |
| AB00698349-05 |
| AB00698349-07 |
| AB2000207 |
| AC1L9FKJ |
| AKOS005145741 |
| Alrex |
| Alrex, Lotemax, Loteprednol etabonate |
| Alrex;Lotemax |
| Androsta-1,4-diene-17-carboxylic acid, 17-((ethoxycarbonyl)oxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11beta,17alpha)- |
| BCP28645 |
| C24H31ClO7 |
| CAS-82034-46-6 |
| CCG-101041 |
| CDDD 5604 |
| CDDD-5604 |
| CHEBI:31784 |
| CHEMBL1200865 |
| chloromethyl (1S,2R,10S,11S,14R,15S,17S)-14-[(ethoxycarbonyl)oxy]-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-14-carboxylate |
| chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-((ethoxycarbonyl)oxy)-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carb |
| chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate |
| Chloromethyl 11beta,17-dihydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate, 17-(ethyl carbonate) |
| chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate |
| CS-0900 |
| D01689 |
| D0X6GN |
| DMKSVUSAATWOCU-HROMYWEYSA-N |
| DSSTox_CID_26468 |
| DSSTox_GSID_46468 |
| DSSTox_RID_81641 |
| DTXSID2046468 |
| GS-3599 |
| GTPL7085 |
| HGP 1 |
| HGP-1 |
| HMS2051F16 |
| HMS2232J09 |
| HMS3715N06 |
| HY-17358 |
| IDR-90102 |
| IDR-90103 |
| K462 |
| Locort |
| Loteflam |
| Lotemax |
| Lotemax (TN) |
| Loteprednol etabonate |
| Loteprednol etabonate (JAN/USAN) |
| Loteprednol etabonate [USAN:JAN] |
| Loteprednol etabonate Opphthalmic suspension |
| Loteprednol Etabonate, >=98% (HPLC) |
| Loterox |
| MLS001424221 |
| MolPort-003-848-424 |
| NC00291 |
| NCGC00164594-01 |
| NCGC00164594-02 |
| P 5604 |
| P-5604 |
| s1669 |
| SCHEMBL23907 |
| SMR000469178 |
| ST24030829 |
| Tox21_112219 |
| Tox21_112219_1 |
| UNII-YEH1EZ96K6 |
| YEH1EZ96K6 |
| ZINC3920673 |
